2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

basal cell carcinomas

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

2

Screening Libraries

1

Peptides

5

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0180
    Imiquimod
    Maximum Cited Publications
    58 Publications Verification

    R 837

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Inflammation/Immunology Cancer
    Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod
  • HY-B1247
    Protoporphyrin IX
    20+ Cited Publications

    PPIX

    		 Endogenous Metabolite Others
    Protoporphyrin IX is a final intermediate in the heme biosynthetic pathway, which acts as a radiation sensitizer enhancing ROS generation even in a hypoxic state and inducing DNA damage. Protoporphyrin IX also acts as a photo sensitizer undergoing photobleaching that occurs through direct degradation by light irradiation. Protoporphyrin IX is formed and accumulated following 5-aminolevulinic acid (5-ALA) (HY-W000450) administration in the tumor cells of rats. Protoporphyrin IX causes selective improvement of basal cell carcinoma when activated red fluorescence of a peak wavelength at 405 nm. Protoporphyrin IX is promising for research of sonodynamic and photodynamic agents for a wide range of cancers, such as bladder cancer and nodular basal cell carcinoma .
    Protoporphyrin IX
  • HY-B0180A
    Imiquimod hydrochloride
    Maximum Cited Publications
    58 Publications Verification

    R 837 hydrochloride

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Neurological Disease Inflammation/Immunology Cancer
    Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo. Imiquimod hydrochloride can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod hydrochloride
  • HY-148807
    Zavondemstat

    QC8222 free base; TACH 101 free base

    		 Histone Demethylase Apoptosis Cancer
    Zavondemstat (QC8222 free base; TACH 101 free base) is an orally active pan-KDM4 inhibitor, with a IC50 ≤ 0.08 μM against human KDM4A-D and a Kᵢ of 0.52 μM against human KDM4C. Zavondemstat induces cell apoptosis, causes S-phase cell cycle arrest, reduces the population of tumor-initiating cells and inhibits cancer cell proliferation. Zavondemstat suppresses tumor growth and induces tumor regression in mouse xenograft models. Zavondemstat can be used for the research of various cancers including colorectal cancer, esophageal squamous cell carcinoma and triple-negative breast cancer .
    Zavondemstat
  • HY-103018
    Gusacitinib
    1 Publications Verification

    ASN-002

    		 JAK Syk Inflammation/Immunology Cancer
    Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .
    Gusacitinib
  • HY-A0169A
    Methyl aminolevulinate hydrochloride
    1 Publications Verification

    		 Reactive Oxygen Species (ROS) Photosensitizer Cancer
    Methyl aminolevulinate hydrochloride is a sensitizer used in photodynamic therapy (PDT). Methyl aminolevulinate hydrochloride penetrates the skin and induces the production of photoactive porphyrins including protoporphyrin IX in cells; upon exposure to appropriate light, it generates ROS, which triggers cellular oxidation and cell death. Methyl aminolevulinate hydrochloride acts as a photo-damage reversing agent through epidermal reconstruction, cytokine-mediated activation of dermal fibroblasts, elastin breakdown, new collagen formation, and compression of dilated capillaries. Methyl aminolevulinate hydrochloride reduces the expression of the proliferation marker Ki-67 and the early skin carcinogenesis marker TP53. Methyl aminolevulinate hydrochloride delays the onset of ultraviolet-induced skin tumors and reduces tumor burden in hairless mice. Methyl aminolevulinate hydrochloride is applicable to research related to actinic keratosis and basal cell carcinoma .
    Methyl aminolevulinate hydrochloride
  • HY-122590
    Glabrescione B

    		Gli Cancer
    Glabrescione B is the first compound that binds the Hedgehog (Hh) modulator Gli1. Glabrescione B impairs its activity by interfering with Gli1-DNA interaction. Glabrescione B inhibits the growth of Hedgehog-dependent tumor cells, the self-renewal ability, and clonogenicity of tumor-derived stem cells .
    Glabrescione B
  • HY-P11228
    FPP29

    		PROTACs Apoptosis DNA/RNA Synthesis Cancer
    FPP29 is a potent peptide-based FOXM1 PROTAC degrader. FPP29 induces ubiquitination and degradation of FOXM1. FPP29 inhibits FOXM1 via the ubiquitin-proteasome degradation pathway. FPP29 induces Apoptosis. FPP29 suppresses tumor growth in hepatocellular carcinoma xenograft models. FPP29 can be used in the research of hepatocellular carcinoma (cell-penetrating peptide: (HY-P0133); VHL ligase ligand: (HY-P11493); linker: (HY-W013664); FOXM1 ligand: (HY-P11494)) .
    FPP29
  • HY-B0180B
    Imiquimod maleate
    Maximum Cited Publications
    58 Publications Verification

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Neurological Disease Inflammation/Immunology Cancer
    Imiquimod maleate (R 837 maleate), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod maleate exhibits antiviral and antitumor effects in vivo. Imiquimod maleate can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod maleate
  • HY-B1247R
    Protoporphyrin IX (Standard)

    PPIX (Standard)

    		 Reference Standards Endogenous Metabolite Others
    Protoporphyrin IX (Standard) is the analytical standard of Protoporphyrin IX. This product is intended for research and analytical applications. Protoporphyrin IX is a final intermediate in the heme biosynthetic pathway, which acts as a radiation sensitizer enhancing ROS generation even in a hypoxic state and inducing DNA damage. Protoporphyrin IX also acts as a photo sensitizer undergoing photobleaching that occurs through direct degradation by light irradiation. Protoporphyrin IX is formed and accumulated following 5-aminolevulinic acid (5-ALA) (HY-W000450) administration in the tumor cells of rats. Protoporphyrin IX causes selective improvement of basal cell carcinoma when activated red fluorescence of a peak wavelength at 405 nm. Protoporphyrin IX is promising for research of sonodynamic and photodynamic agents for a wide range of cancers, such as bladder cancer and nodular basal cell carcinoma .
    Protoporphyrin IX (Standard)
  • HY-113965
    CUR61414
    1 Publications Verification

    		 Hedgehog Smo Apoptosis Inflammation/Immunology
    CUR61414 is a novel, potent and cell permeable Hedgehog signaling pathway inhibitor (IC50 =100-200 nM). CUR61414 is a small-molecule aminoproline class compound and selectively binds to smoothened (Smo) with a Ki value of 44 nM. CUR-61414 can induce apoptosis in cancer cells without affecting neighboring non-tumor cells .
    CUR61414
  • HY-B1247A
    Protoporphyrin IX disodium
    20+ Cited Publications

    PPIX disodium

    		 Endogenous Metabolite Cancer
    Protoporphyrin IX disodium is a final intermediate in the heme biosynthetic pathway, which acts as a radiation sensitizer enhancing ROS generation even in a hypoxic state and inducing DNA damage. Protoporphyrin IX disodium also acts as a photo sensitizer undergoing photobleaching that occurs through direct degradation by light irradiation. Protoporphyrin IX disodium is formed and accumulated following 5-aminolevulinic acid (5-ALA) (HY-W000450) administration in the tumor cells of rats. Protoporphyrin IX disodium causes selective improvement of basal cell carcinoma when activated red fluorescence of a peak wavelength at 405 nm. Protoporphyrin IX disodium is promising for research of sonodynamic and photodynamic agents for a wide range of cancers, such as bladder cancer and nodular basal cell carcinoma .
    Protoporphyrin IX disodium
  • HY-161740
    PHTPP-1304

    		AUTOTACs Estrogen Receptor/ERR Autophagy Cancer
    PHTPP-1304 is a PHTPP-based autophagy targeting chimera (AUTOTAC). PHTPP-1304 induces the degradation of estrogen receptor ERβ through the autophagy pathway, rather than ubiquitination (DC50 ≈ 2 nM, in HEK293T cells; < 100 nM in ACHN renal carcinoma and MCF-7 breast cancer cells). PHTPP-1304 can induce the self-oligomerization of p62. PHTPP-1304 can be used to study various cancers mediated by ERβ .
    PHTPP-1304
  • HY-B0180R
    Imiquimod (Standard)

    R 837 (Standard)

    		 Reference Standards Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Inflammation/Immunology Cancer
    Imiquimod (Standard) is the analytical standard of Imiquimod. This product is intended for research and analytical applications. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod (Standard)
  • HY-15960
    PWT-33597 free base

    VDC-597 free base

    		 PI3K mTOR Apoptosis Cancer
    PWT-33597 (VDC-597) free base is a dual inhibitor of PI3Kα and mTOR, which can effectively block the signaling downstream of PI3K and mTOR. PWT-33597 free base is capable of inducing tumor cell apoptosis and inhibiting tumor growth. PWT-33597 free base has anti-tumor activity and can be used in the research of tumors such as renal cell carcinoma .
    PWT-33597 free base
  • HY-179392
    Sunitinib-platinum(IV) prodrug-1

    		Apoptosis DNA Alkylator/Crosslinker VEGFR PDGFR Cancer
    Sunitinib-platinum(IV) prodrug-1 (Complex A) is a Pt(IV) prodrug based on Cisplatin (HY-17394), and this design aims to enable Pt(IV) to be reduced to active Pt(II) under intracellular reducing conditions, while simultaneously releasing a derivative of Sunitinib (HY-10255A) with tyrosine kinase inhibitor (TKI) activity. Sunitinib-platinum(IV) prodrug-1 exhibits excellent cytotoxicity against renal cell carcinoma (RCC), causing DNA crosslinking and apoptosis. Sunitinib-platinum(IV) prodrug-1 inhibits the VEGFR/PDGFR signaling pathway, suppressing tumor growth and angiogenesis. Sunitinib-platinum(IV) prodrug-1 can be used for research on renal cell carcinoma .
    Sunitinib-platinum(IV) prodrug-1
  • HY-143400
    HSP70-IN-3

    		HSP Hedgehog Cancer
    HSP70-IN-3 is a potent HSP70 inhibitor (IC50s of 1.1 and 1.9 μM in ASZ001 and C3H10T1/2, respectively). HSP70-IN-3 has anti-Hh (Hedgehog signaling) activity and anti-proliferative activity and reduces expression of the oncogenic transcription factor GLI1 .
    HSP70-IN-3
  • HY-16475
    TAK-441

    		Hedgehog Cancer
    TAK-441 is a highly potent and orally active hedgehog (Hh) signaling inhibitor with an IC50value of 4.4 nM. TAK-441 has strong antitumor activity in solid tumors .
    TAK-441
  • HY-107408
    SANT 2

    		Hedgehog Gli Metabolic Disease Cancer
    SANT 2 is a potent Hh-signaling pathway antagonist. SANT 2 interferes with the expression of Gli1. SANT 2 causes developmental delay in medaka embryos. SANT 2 has the potential for the research of several malignancies including Gorlin syndrome (a disorder predisposing to basal cell carcinoma, medulloblastoma and rhabdomyosarcoma), prostate, pancreatic and breast cancers .
    SANT 2
  • HY-103018A
    Gusacitinib hydrochloride

    ASN-002 hydrochloride

    		 JAK Syk Inflammation/Immunology Cancer
    Gusacitinib (ASN-002) hydrochloride is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib hydrochloride rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib hydrochloride can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .
    Gusacitinib hydrochloride
  • HY-B0180BR
    Imiquimod maleate (Standard)

    		Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Reference Standards Infection Inflammation/Immunology Cancer
    Imiquimod (maleate) (Standard) is the analytical standard of Imiquimod (maleate). This product is intended for research and analytical applications. Imiquimod maleate (R 837 maleate), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod maleate exhibits antiviral and antitumor effects in vivo. Imiquimod maleate can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod maleate (Standard)
  • HY-B0180AR
    Imiquimod hydrochloride (Standard)

    R 837 hydrochloride (Standard)

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Reference Standards Infection Inflammation/Immunology Cancer
    Imiquimod (hydrochloride) (Standard) is the analytical standard of Imiquimod (hydrochloride). This product is intended for research and analytical applications. Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo. Imiquimod hydrochloride can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod hydrochloride (Standard)
  • HY-10226
    JNJ-16241199

    R306465

    		 Apoptosis HDAC Cancer
    JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases the expression of p21 waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study .
    JNJ-16241199
  • HY-A0169
    Methyl aminolevulinate

    		Reactive Oxygen Species (ROS) Photosensitizer Cancer
    Methyl aminolevulinate is a sensitizer used in photodynamic therapy (PDT). Methyl aminolevulinate penetrates the skin and induces the production of photoactive porphyrins including protoporphyrin IX in cells; upon exposure to appropriate light, it generates ROS, which triggers cellular oxidation and cell death. Methyl aminolevulinate acts as a photo-damage reversing agent through epidermal reconstruction, cytokine-mediated activation of dermal fibroblasts, elastin breakdown, new collagen formation, and compression of dilated capillaries. Methyl aminolevulinate reduces the expression of the proliferation marker Ki-67 and the early skin carcinogenesis marker TP53. Methyl aminolevulinate delays the onset of ultraviolet-induced skin tumors and reduces tumor burden in hairless mice. Methyl aminolevulinate is applicable to research related to actinic keratosis and basal cell carcinoma .
    Methyl aminolevulinate
  • HY-117803
    CP 461 free base

    OSI-461 free base

    		 Apoptosis Cancer
    CP 461 free base (OSI-461 free base) is a novel pro-apoptotic compound with the activity of inhibiting cyclic guanosine monophosphate phosphodiesterase. CP 461 free base exhibits growth inhibitory activity against a variety of human tumor cell lines in vitro. CP 461 free base selectively induces apoptosis in cancer cell lines but has no effect on normal cells. CP 461 free base can be used in the study of renal cell carcinoma, prostate cancer and Crohn's disease .
    CP 461 free base
  • HY-157528
    CJ28

    		Endogenous Metabolite Cancer
    CJ28 is a cortisol biosynthesis inhibitor that significantly inhibits basal and stimulated cortisol production in human adrenal carcinoma cell lines. CJ28 exhibits inhibitory effects by reducing steroidogenesis and de novo cholesterol biosynthesis .
    CJ28
  • HY-147743
    SMO-IN-1

    		Smo Cancer
    SMO-IN-1 (Compound 15) is an orally active Smoothened (SMO) inhibitor with an EC50 of 89 nM against sonic Hh protein (shh) .
    SMO-IN-1
  • HY-158762
    TK-642

    		SHP2 Cancer
    TK-642 is a highly active, selective, orally activity SHP2 inhibitor based on pyrazole and pyrazine (IC50=2.7 nmol/L). TK-642 can effectively inhibit the proliferation of esophageal carcinoma cells and induce cell apoptosis. TK-642 can be used in the study of esophageal cancer .
    TK-642
  • HY-147744
    AZD7254

    		Smo Cancer
    AZD7254 is an orally active Smoothened (SMO) inhibitor with an EC50 of 1.0 nM against sonic Hh protein (shh) .
    AZD7254
  • HY-W014394R
    Vanillyl butyl ether (Standard)

    		TRP Channel Reference Standards Parasite Cardiovascular Disease
    Protoporphyrin IX (Standard) is the analytical standard of Protoporphyrin IX. This product is intended for research and analytical applications. Protoporphyrin IX is a final intermediate in the heme biosynthetic pathway, which acts as a radiation sensitizer enhancing ROS generation even in a hypoxic state and inducing DNA damage. Protoporphyrin IX also acts as a photo sensitizer undergoing photobleaching that occurs through direct degradation by light irradiation. Protoporphyrin IX is formed and accumulated following 5-aminolevulinic acid (5-ALA) (HY-W000450) administration in the tumor cells of rats. Protoporphyrin IX causes selective improvement of basal cell carcinoma when activated red fluorescence of a peak wavelength at 405 nm. Protoporphyrin IX is promising for research of sonodynamic and photodynamic agents for a wide range of cancers, such as bladder cancer and nodular basal cell carcinoma .
    Vanillyl butyl ether (Standard)
  • HY-164399A
    SST0116CL1 free base

    		HSP ERK CDK Akt Cancer
    SST0116CL1 free base is a HSP90 inhibitor (IC50: 0.21 μM). SST0116CL1 free base binds to the ATP binding pocket of Hsp90, and interferes with Hsp90 chaperone function thus resulting in client protein (EGFR, CDK4 and AKT) degradation. SST0116CL1 free base induces degradation of Her2 in BT-474 cell (IC50: 0.2 μM). SST0116CL1 free base has antiproliferative activity and inhibits tumor growth. SST0116CL1 free base has antiproliferative activity and inhibits tumor growth. SST0116CL1 free base can be used for the study of leukemia, gastric and ovarian carcinoma .
    SST0116CL1 free base
  • HY-168085
    CV-4-26

    		YAP Apoptosis Cancer
    CV-4-26 (Compound 22) is a covalent inhibitor of TEAD. CV-4-26 inhibits YAP/TEAD-based transcription, leading to the reduction of CTGF and CYR61 expression. CV-4-26 inhibits Huh7 and HepG2 cell colony formation, induces cell cycle arrest, and apoptosis. CV-4-26 shows antitumor activity against hepatocellular carcinoma (HCC) and hepatoblastoma (HB) .
    CV-4-26
  • HY-162372
    Hedgehog IN-6

    		Hedgehog Smo Cancer
    Hedgehog IN-6 (Compound Q29) is a Hedgehog (Hh) inhibitor that can be used in cancer research. Hedgehog IN-6 inhibits the hedgehog (Hh) pathway by binding to the cysteine-rich domain (CRD) of Smoothened (Smo) and blocking its cholesterization .
    Hedgehog IN-6
  • HY-B0180C
    Imiquimod dihydrochloride

    R 837 dihydrochloride

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Inflammation/Immunology Cancer
    Imiquimod (R 837) dihydrochloride, an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod dihydrochloride
  • HY-19873
    SL-052

    		Photosensitizer Cancer
    SL-052 is a hypocrellin-based photosensitizer that has recently shown promising results in clinical and preclinical testing for cancer photodynamic therapy (PDT). SL-052 is encapsulated in biodegradable polylactic-co-glycolic acid (PLGA) polymer nanoparticles optimized using single emulsion solvent evaporation technology. The SL-052-PLGA nanoparticles were more effective in PDT treatment of subcutaneous SCCVII squamous cell carcinoma compared to polyvinylpyrrolidone (PVP)-based and standard liposomal SL-052 formulations. A longer time interval between drug injection and tumor illumination can improve tumor cure rates, and SL-052-PLGA nanoparticles showed the best therapeutic effect among all SL-052 formulations.
    SL-052
  • HY-103018S
    Gusacitinib-d4

    ASN-002-d4

    		 Isotope-Labeled Compounds JAK Syk Inflammation/Immunology Cancer
    Gusacitinib-d4 (ASN-002-d4) is the deuterium labeled Gusacitinib (HY-103018). Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .
    Gusacitinib-d4
  • HY-111137
    Puquitinib

    XC-302 free base

    		 Akt Cancer
    Puquitinib (XC-302 free base) is a multi-target inhibitor with the activity of inducing autophagy in nasopharyngeal carcinoma cells by inhibiting the PI3K/AKT/mTOR signaling pathway. Puquitinib was able to inhibit the proliferation of CNE-2 cells, showing a dose-dependent antiproliferative effect. Puquitinib induced the formation of autophagosomes and autolysosomes in CNE-2 cells, which were observed by fluorescence microscopy and electron microscopy. Puquitinib promoted the formation of LC3-II and increased the expression of beclin 1, while reducing the level of p62. Puquitinib inhibited the PI3K/AKT/mTOR pathway by reducing the expression of p-AKT and p-mTOR. Puquitinib also induced apoptosis in CNE-2 cells, and when autophagy was inhibited, the apoptosis rate was reduced, which means that autophagy may interact with apoptosis to induce cell death .
    Puquitinib
  • HY-182721
    Pipinib

    		PI4K Hedgehog Cancer
    Pipinib is an ATP-competitive and selective phosphatidylinositol 4-kinase IIIb (PI4KB) inhibitor with an IC50 of 2.2 μM. Pipinib reduces intracellular PI4P levels. Pipinib inhibits GLI-mediated transcription, the expression of Hedgehog target genes, and blocks the trafficking of Smoothened to cilia. Pipinib can be used in the research of basal cell carcinoma and medulloblastoma .
    Pipinib
  • HY-183098
    UNC8209

    		PROTACs IKK Apoptosis Cancer
    UNC8209 is a selective PROTAC-based TANK-binding kinase 1 (TBK1) degrader. UNC8209 recruits cereblon (CRBN) to mediate ubiquitin-proteasome pathway-dependent TBK1 degradation and reduces AAK1, GAK, and AURKA abundance. UNC8209 suppresses tumor cell proliferation, impairs in vivo tumor growth, inhibits colony and clonogenic growth and enhances tumor cell sensitivity to TNFα or IFN-γ. UNC8209 modulates cell cycle and induces mild apoptosis. UNC8209 can be used for the research of clear cell renal cell carcinoma, non-small cell lung cancer, pancreatic ductal adenocarcinoma .
    UNC8209
  • HY-103018R
    Gusacitinib (Standard)

    ASN-002 (Standard)

    		 Reference Standards JAK Syk Inflammation/Immunology Cancer
    Gusacitinib (Standard) is the analytical standard of Gusacitinib (HY-103018). This product is intended for research and analytical applications. Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .
    Gusacitinib (Standard)
  • HY-A0169AR
    Methyl aminolevulinate hydrochloride (Standard)

    		Reactive Oxygen Species (ROS) Reference Standards Photosensitizer Inflammation/Immunology Cancer
    Methyl aminolevulinate hydrochloride (Standard) is the analytical standard of Methyl aminolevulinate hydrochloride. This product is intended for research and analytical applications. Methyl aminolevulinate hydrochloride is a sensitizer used in photodynamic therapy (PDT). Methyl aminolevulinate hydrochloride penetrates the skin and induces the production of photoactive porphyrins including protoporphyrin IX in cells; upon exposure to appropriate light, it generates ROS, which triggers cellular oxidation and cell death. Methyl aminolevulinate hydrochloride acts as a photo-damage reversing agent through epidermal reconstruction, cytokine-mediated activation of dermal fibroblasts, elastin breakdown, new collagen formation, and compression of dilated capillaries. Methyl aminolevulinate hydrochloride reduces the expression of the proliferation marker Ki-67 and the early skin carcinogenesis marker TP53. Methyl aminolevulinate hydrochloride delays the onset of ultraviolet-induced skin tumors and reduces tumor burden in hairless mice. Methyl aminolevulinate hydrochloride is applicable to research related to actinic keratosis and basal cell carcinoma .
    Methyl aminolevulinate hydrochloride (Standard)
  • HY-10226R
    JNJ-16241199 (Standard)

    R306465 (Standard)

    		 Reference Standards Apoptosis HDAC Cancer
    JNJ-16241199 (Standard) is the analytical standard of JNJ-16241199 (HY-10226). This product is intended for research and analytical applications. JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases the expression of p21waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study .
    JNJ-16241199 (Standard)
  • HY-N17074
    Ethyl (10E,12E)-9-oxooctadeca-10,12-dienoate

    		Others Cancer
    Ethyl (10E,12E)-9-oxooctadeca-10,12-dienoate is a conjugated ketonic fatty acid that can be found in the leaves of Vernicia fordii. Ethyl (10E,12E)-9-oxooctadeca-10,12-dienoate shows no significant cytotoxic activity against cancer cells .
    Ethyl (10E,12E)-9-oxooctadeca-10,12-dienoate
  • HY-182759
    MN33-47

    		DNA Alkylator/Crosslinker Topoisomerase Caspase Bcl-2 Family Apoptosis Cancer
    MN33-47 is a multi-target anti-tumor compound with broad-spectrum anti-proliferative activity. MN33-47 relieves the inhibition of the mitochondrial apoptosis pathway by downregulating the anti-apoptotic protein Bcl-2, while activating caspase-3 and inhibiting Topoisomerase I activity, thereby promoting its degradation through the ubiquitin-proteasome and autophagy-lysosome pathways. MN33-47 can also induce DNA cross-linking and G2/M cell cycle arrest, inhibit cancer cell migration and activate the mitochondrial apoptosis pathway, thus exerting potent anti-tumor effects. MN33-47 can improve the water solubility of SN-38 (HY-13704), and exhibits dose-dependent tumor growth inhibition effects in CT26 tumor-bearing mouse models without obvious toxic and side effects. MN33-47 can be used in related studies on colorectal adenocarcinoma, cervical adenocarcinoma, hepatocellular carcinoma, alveolar basal epithelial adenocarcinoma, gastric cancer and colon cancer .
    MN33-47

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: